Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$181.9 million.

  • Nurix Therapeutics' Free Cash Flow fell 34.97% to -$60.1 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$241.4 million, marking a year-over-year decrease of 125.79%. This contributed to the annual value of -$181.9 million for FY2024, which is 102.59% down from last year.
  • Per Nurix Therapeutics' latest filing, its Free Cash Flow stood at -$181.9 million for FY2024, which was down 102.59% from -$89.8 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Free Cash Flow ranged from a high of -$4.6 million in FY2020 and a low of -$181.9 million during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$172.1 million (2022), whereas its average is -$147.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 1,843.15% in 2021, then soared by 47.83% in 2023.
  • Nurix Therapeutics' Free Cash Flow (Yearly) stood at -$4.6 million in 2020, then tumbled by 1,843.15% to -$90.0 million in 2021, then slumped by 91.11% to -$172.1 million in 2022, then surged by 47.83% to -$89.8 million in 2023, then crashed by 102.59% to -$181.9 million in 2024.